Innovent Biologics

Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

Friday, March 20, 2015

Eli Lilly and Innovent Biologics, a biopharmaceutical company in China, have inked a biotech drug development collaboration to collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.

[Read More]

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

[Read More]

Aragen Bioscience, Innovent Biologics collaborate on biotherapeutic product development

Wednesday, April 3, 2013

Aragen Bioscience, a privately held CRO, and Innovent Biologics, a privately held biopharmaceutical company, have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Aragen Bioscience will develop robust CHO cell lines and assess critical product quality attributes for various antibodies and protein therapeutics. 

[Read More]